2.50
Hdl Handle:
http://hdl.handle.net/10541/74918
Title:
The future of fulvestrant ("Faslodex").
Authors:
Howell, Anthony ( 0000-0002-3879-5991 )
Abstract:
Changes in clinical practice regarding favoured first-line and adjuvant treatments for postmenopausal women with advanced breast cancer (ABC) mean that it is becoming increasingly important to identify agents that are effective following aromatase inhibitor (AI) failure as well as tamoxifen failure. Fulvestrant ("Faslodex") is a new oestrogen receptor (ER) antagonist with no agonist effects that binds, blocks and degrades the ER. Fulvestrant is at least as effective as anastrozole following tamoxifen failure and also shows activity after progression on AIs. Its very good tolerability profile and novel mode of action, might offer potential for the use of fulvestrant in combination regimens, and there is also scope for investigating the use of loading and higher dose regimens in an attempt to further enhance efficacy. Here, the rationale and evidence for the efficacy of fulvestrant following AI failure and its combination with AIs and novel agents such as gefitinib and trastuzumab will be reviewed. The ongoing clinical development programme for fulvestrant will more fully the role of this valuable new agent in the treatment of postmenopausal ABC.
Affiliation:
CRUK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. anthony.howell@christie-tr.nwest.nhs.uk
Citation:
The future of fulvestrant ("Faslodex"). 2005, 31 Suppl 2:S26-33 Cancer Treat. Rev.
Journal:
Cancer Treatment Reviews
Issue Date:
2005
URI:
http://hdl.handle.net/10541/74918
DOI:
10.1016/j.ctrv.2005.08.007
PubMed ID:
16198056
Type:
Article
Language:
en
ISSN:
0305-7372
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorHowell, Anthony-
dc.date.accessioned2009-07-22T10:16:36Z-
dc.date.available2009-07-22T10:16:36Z-
dc.date.issued2005-
dc.identifier.citationThe future of fulvestrant ("Faslodex"). 2005, 31 Suppl 2:S26-33 Cancer Treat. Rev.en
dc.identifier.issn0305-7372-
dc.identifier.pmid16198056-
dc.identifier.doi10.1016/j.ctrv.2005.08.007-
dc.identifier.urihttp://hdl.handle.net/10541/74918-
dc.description.abstractChanges in clinical practice regarding favoured first-line and adjuvant treatments for postmenopausal women with advanced breast cancer (ABC) mean that it is becoming increasingly important to identify agents that are effective following aromatase inhibitor (AI) failure as well as tamoxifen failure. Fulvestrant ("Faslodex") is a new oestrogen receptor (ER) antagonist with no agonist effects that binds, blocks and degrades the ER. Fulvestrant is at least as effective as anastrozole following tamoxifen failure and also shows activity after progression on AIs. Its very good tolerability profile and novel mode of action, might offer potential for the use of fulvestrant in combination regimens, and there is also scope for investigating the use of loading and higher dose regimens in an attempt to further enhance efficacy. Here, the rationale and evidence for the efficacy of fulvestrant following AI failure and its combination with AIs and novel agents such as gefitinib and trastuzumab will be reviewed. The ongoing clinical development programme for fulvestrant will more fully the role of this valuable new agent in the treatment of postmenopausal ABC.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshBreast Neoplasms-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshDisease Progression-
dc.subject.meshDose-Response Relationship, Drug-
dc.subject.meshDrug Resistance, Neoplasm-
dc.subject.meshEstradiol-
dc.subject.meshEstrogen Antagonists-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshPostmenopause-
dc.subject.meshReceptor, erbB-2-
dc.subject.meshReceptors, Estrogen-
dc.titleThe future of fulvestrant ("Faslodex").en
dc.typeArticleen
dc.contributor.departmentCRUK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. anthony.howell@christie-tr.nwest.nhs.uken
dc.identifier.journalCancer Treatment Reviewsen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.